NuPathe Inc. to Report Second Quarter 2010 Financial Results and Hold Conference Call

CONSHOHOCKEN, PA--(Marketwire - September 07, 2010) - NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, today announces that it will report second quarter 2010 financial results on September 14, 2010, before the U.S. financial markets open.

NuPathe will host a conference call on the second quarter 2010 financial results at 8:45 am EDT on the same day. Although there will not be a question and answer session following this presentation, the Company plans to have question and answer sessions on future calls. To participate on the live call, please dial 888-299-7230 (domestic) or +1-719-457-2558 (international), and provide the participant passcode 4865914, five to ten minutes ahead of the start of the call. A replay of the call will be available for one month within a few hours after the call ends. Investors may listen to the replay for one month following the call by dialing 888-203-1112 (domestic) or +1-719-457-0820 (international), with the passcode 4865914.

A live audio webcast of the call will be available via the “Investor Relations” page of the NuPathe website, www.nupathe.com. Please log on through NuPathe’s website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will be archived on NuPathe’s website for one month following the call.

About NuPathe

NuPathe Inc. is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe’s most advanced product candidate, Zelrix™, is a transdermal patch for the treatment of migraine. Zelrix actively delivers sumatriptan, the most widely prescribed migraine medication, through the skin in a controlled manner using its proprietary SmartRelief™ technology.

In addition, NuPathe has two other proprietary product candidates in preclinical development that address large market opportunities: NP201 for the continuous symptomatic treatment of Parkinson’s disease, and NP202 for the long-term treatment of schizophrenia and bipolar disorder.